Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
Conditions
Interventions
FC084CSA tablets
Locations
1
China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Start Date
March 1, 2023
Primary Completion Date
March 18, 2025
Completion Date
March 18, 2025
Last Updated
August 7, 2025
NCT06658951
NCT06717750
NCT07292402
NCT06912152
NCT07480733
NCT07363369
Lead Sponsor
FindCure Biosciences (ZhongShan) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions